Scholarlink

Background <p>Despite durable benefits of ipilimumab and nivolumab in metastatic renal cell carcinoma (mRCC), early progressive disease (PD), defined as disease progression within 3&#xa0;months, occurs, and its predictors remain unclear. We aimed to investigate the clinical factors associated with early PD in patients with mRCC treated with this regimen.</p> Methods <p>A retrospective analysis of a multi-institutional database identified 193 patients with mRCC treated with ipilimumab plus nivolumab. Logistic regression analyses assessed associations between clinical factors and early PD.</p> Results <p>During a median follow-up of 17&#xa0;months, patients had median overall (OS) and progression-free survival (PFS) of 35 and 14&#xa0;months, respectively. Objective response and PD rates were 49.9% and 24.9%, respectively. Patients with early PD had significantly worse OS than those with non-early PD (10 vs. 42&#xa0;months; <i>P</i> = 0.0002). Multivariate analyses identified bone metastasis and performance status (PS) as independent indicators of early PD (<i>P</i> = 0.03 and 0.01, respectively). Early PD rates varied by metastatic site (lung, 19.3%; bone, 31.2%; brain, 10%; and liver, 30%). Patients with clear-cell RCC had a median OS of 48&#xa0;months and PFS of 22&#xa0;months. The identified variables of early PD were consistent across all patient populations evaluated.</p> Conclusions <p>Bone metastasis and PS predict early PD in patients with mRCC treated with ipilimumab plus nivolumab, with antitumor effect of the regimen varying by metastatic site. Clarifying the characteristics of early PD may guide clinical decision-making in treatment selection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab

  • 期刊论文

  • 发表日期：

    2025年9月5日

查看全文
  • Keiichiro Mori,
  • Takafumi Yanagisawa,
  • Tatsushi Kawada,
  • Satoshi Katayama,
  • Ryoichi Maenosono,
  • Takuya Tsujino,
  • Takeshi Hashimoto,
  • Yosuke Hirasawa,
  • Lan Inoki,
  • Shingo Toyoda,
  • Takuhisa Nukaya,
  • Kiyoshi Takahara,
  • Wataru Fukuokaya,
  • Fumihiko Urabe,
  • Takehiro Iwata,
  • Kensuke Bekku,
  • Yoshio Ohno,
  • Ryoichi Shiroki,
  • Kazutoshi Fujita,
  • Haruhito Azuma,
  • Motoo Araki,
  • Takahiro Kimura

摘要

Background

Despite durable benefits of ipilimumab and nivolumab in metastatic renal cell carcinoma (mRCC), early progressive disease (PD), defined as disease progression within 3 months, occurs, and its predictors remain unclear. We aimed to investigate the clinical factors associated with early PD in patients with mRCC treated with this regimen.

Methods

A retrospective analysis of a multi-institutional database identified 193 patients with mRCC treated with ipilimumab plus nivolumab. Logistic regression analyses assessed associations between clinical factors and early PD.

Results

During a median follow-up of 17 months, patients had median overall (OS) and progression-free survival (PFS) of 35 and 14 months, respectively. Objective response and PD rates were 49.9% and 24.9%, respectively. Patients with early PD had significantly worse OS than those with non-early PD (10 vs. 42 months; P = 0.0002). Multivariate analyses identified bone metastasis and performance status (PS) as independent indicators of early PD (P = 0.03 and 0.01, respectively). Early PD rates varied by metastatic site (lung, 19.3%; bone, 31.2%; brain, 10%; and liver, 30%). Patients with clear-cell RCC had a median OS of 48 months and PFS of 22 months. The identified variables of early PD were consistent across all patient populations evaluated.

Conclusions

Bone metastasis and PS predict early PD in patients with mRCC treated with ipilimumab plus nivolumab, with antitumor effect of the regimen varying by metastatic site. Clarifying the characteristics of early PD may guide clinical decision-making in treatment selection.